Free tool
FAERS Monitor: Lunsumio Velo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761263 or its brand name (Lunsumio Velo, Mosunetuzumab-Axgb). Reports on generic versions are filed under their own applications.
Reports
1,107
Serious
950
86% of reports
Hospitalization
467
Death reported
156
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome299
- disease progression134
- neutropenia96
- off label use77
- pyrexia72
- covid-1969
- death52
- pneumonia51
- malignant neoplasm progression46
- rash44
- covid-19 pneumonia41
- thrombocytopenia34
- disorientation32
- neurological symptom31
- vasogenic cerebral oedema31
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 16 |
| 2021 | 52 |
| 2022 | 83 |
| 2023 | 335 |
| 2024 | 104 |
| 2025 | 195 |
| 2026 | 313 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,052 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vasogenic cerebral oedemaSignal | 31 | 855.7 | 600.0 | 24,514 |
| cytokine release syndromeSignal | 299 | 287.5 | 260.7 | 83,887 |
| neurological symptomSignal | 31 | 103.7 | 73.2 | 3,034 |
| covid-19 pneumoniaSignal | 41 | 66.2 | 49.0 | 2,561 |
| disease progressionSignal | 134 | 21.5 | 18.4 | 2,616 |
| disorientationSignal | 32 | 15.4 | 10.9 | 416 |
| neutropeniaSignal | 96 | 13.4 | 11.1 | 1,098 |
| malignant neoplasm progressionSignal | 46 | 8.5 | 6.4 | 300 |
| covid-19Signal | 69 | 7.5 | 5.9 | 384 |
| thrombocytopeniaSignal | 34 | 5.8 | 4.2 | 130 |
| pyrexiaSignal | 72 | 4.0 | 3.2 | 159 |
| pneumoniaSignal | 51 | 3.0 | 2.3 | 67 |
| rash | 44 | 1.9 | 1.4 | 19 |
| off label use | 77 | 1.7 | 1.3 | 21 |
| death | 52 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.